Based on the morphological, immunohistochemical, molecular findings and the good response to receptor tyrosine kinases inhibitors, the final diagnosis of the inflammatory myofibroblastic tumor with a previously undescribed ROS1 fusion is made, although ALK rearrangement is negative. Here, ROS1 is linked to inflammatory myofibroblastic tumor.